- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Injection solution of benralizumab.
Severe eosinophilic asthma: Add-on maintenance treatment
Patients may self administer following appropriate training.
Continuation of treatment should be assessed on the yearly basis taking into account the disease severity, level of exacerbation control and counts of blood eosinophils.
30mg by subcutaneous injection every 4 weeks for the first 3 doses, followed by 30mg every 8 weeks thereafter.
Additional Dosage Information
In the event of a missed dose benralizumab should be administered as soon as possible following the planned dates and avoiding the double dose.
Subcutaneous injection into the thigh or abdomen.
The upper arm can be used if administered by a healthcare professional or a carer.
Children under 18 years
Precautions and Warnings
History of anaphylaxis
Susceptibility to helminth infections
Not suitable for acute treatment of asthma
Avoid abrupt withdrawal of concurrent corticosteroids
Treat helminth infection before initiation of therapy
Treatment to be prescribed under the supervision of a specialist
Avoid injection into broken or bruised skin
Consider temporary discontinuation if helminth infection occurs
Discontinue if hypersensitivity reactions occur
Advise patient to consult physician if condition worsens / does not improve
Pregnancy and Lactation
Use benralizumab with caution during pregnancy.
The manufacturer advises that it is preferable to avoid benralizumab during pregnancy.
There is an increased potential for exposure to the fetus during the second and third trimester of pregnancy.
Animal studies do not show any maternal, embryo-foetal and postnatal effects of benralizumab administration.
Benralizumab is contraindicated during breastfeeding.
The manufacturer advises that the patient either discontinues benralizumab or discontinues breastfeeding.
The presence of benralizumab in human breast milk is unknown but due to its high molecular weight it is predicted that the amount in milk is likely to be very low.
Injection site reactions
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: November 2021
Summary of Product Characteristics: Fasenra 30mg solution for injection in pre-filled syringe and in pre-filled pen. AstraZeneca UK Limited. Revised January 2021.
US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://www.ncbi.nlm.nih.gov/books/NBK501922/
Benralizumab Last revised: 20 July 2020
Last accessed: 30 November 2021
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.